KalVista Pharmaceuticals Statistics
Total Valuation
KALV has a market cap or net worth of $413.13 million. The enterprise value is $283.57 million.
Important Dates
The next estimated earnings date is Tuesday, December 31, 2024, before market open.
| Earnings Date | Dec 31, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
KALV has 49.42 million shares outstanding. The number of shares has increased by 30.22% in one year.
| Current Share Class | 49.42M |
| Shares Outstanding | 49.42M |
| Shares Change (YoY) | +30.22% |
| Shares Change (QoQ) | +1.00% |
| Owned by Insiders (%) | 1.51% |
| Owned by Institutions (%) | 62.91% |
| Float | 29.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 14.94 |
| PB Ratio | 2.70 |
| P/TBV Ratio | 3.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.87, with a Debt / Equity ratio of 0.05.
| Current Ratio | 6.87 |
| Quick Ratio | 6.71 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -125.90% and return on invested capital (ROIC) is -81.78%.
| Return on Equity (ROE) | -125.90% |
| Return on Assets (ROA) | -71.62% |
| Return on Capital (ROIC) | -81.78% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.04M |
| Employee Count | 150 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.41% in the last 52 weeks. The beta is 0.83, so KALV's price volatility has been lower than the market average.
| Beta (5Y) | 0.83 |
| 52-Week Price Change | -24.41% |
| 50-Day Moving Average | 10.40 |
| 200-Day Moving Average | 11.67 |
| Relative Strength Index (RSI) | 36.75 |
| Average Volume (20 Days) | 421,552 |
Short Selling Information
The latest short interest is 7.26 million, so 14.69% of the outstanding shares have been sold short.
| Short Interest | 7.26M |
| Short Previous Month | 7.37M |
| Short % of Shares Out | 14.69% |
| Short % of Float | 24.86% |
| Short Ratio (days to cover) | 23.75 |
Income Statement
| Revenue | n/a |
| Gross Profit | -91.00M |
| Operating Income | -171.63M |
| Pretax Income | -126.64M |
| Net Income | -156.39M |
| EBITDA | -170.76M |
| EBIT | -171.63M |
| Earnings Per Share (EPS) | -$3.66 |
Full Income StatementBalance Sheet
The company has $135.78 million in cash and $6.21 million in debt, giving a net cash position of $129.56 million or $2.62 per share.
| Cash & Cash Equivalents | 135.78M |
| Total Debt | 6.21M |
| Net Cash | 129.56M |
| Net Cash Per Share | $2.62 |
| Equity (Book Value) | 133.99M |
| Book Value Per Share | 3.10 |
| Working Capital | 130.10M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$122.54 million and capital expenditures -$163,000, giving a free cash flow of -$122.70 million.
| Operating Cash Flow | -122.54M |
| Capital Expenditures | -163,000 |
| Free Cash Flow | -122.70M |
| FCF Per Share | -$2.48 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |